ClinicalTrials.gg
CompletedNCT02849899PRODIGUpdated Oct 6, 2026

Prevention of Diabetes After Transplantation by Vildagliptin in the Early Post-transplant Period

A Phase 3 interventional study of Vildagliptin and Placebo in Disorder Related to Renal Transplantation and Diabetes, sponsored by Centre Hospitalier Universitaire de Besancon. Completed at 1 site in France. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Centre Hospitalier Universitaire de Besancon · Phase 3, Interventional, and Prevention

How we know

Updated Oct 6, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
47
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 26 studies testing vildagliptin in Diabetes Mellitus — none open to participants now, none under way, none of them phase 3. Vildagliptin · Diabetes Mellitus.

Enrollment
15th of 26
47 · median 53
Started
2018
the only one that year
Phase 3
5 of 26
none open now
Registered
23rd of 26
by date
Lead sponsor
1 of 26
Centre Hospitalier Universitaire de Besancon

Among the 26 studies testing vildagliptin in Diabetes Mellitus, this one is the 15th largest by enrollment, is the only one that started in 2018, is one of 5 in phase 3, and was the 23rd registered.

Diabetes Mellitus

8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

None of the 26 studies testing vildagliptin in Diabetes Mellitus is open now. The open studies under Diabetes Mellitus, anywhere →

About vildagliptin

Vildagliptin: first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 26 studies testing vildagliptin in Diabetes Mellitus as a file.
02

Study summary

Post-transplant diabetes affects 15 to 20% of renal transplant patients and contributes to increased morbidity and reduced survival of transplants and patients. Corticosteroids, anti-calcineurin and mammilian Target OF Rapamycin (mTOR) inhibitors have a major diabetogenic impact and greatly contribute to the increase in diabetes prevalence after transplantation.

There are to date few studies concerning the pharmacological prevention of post-transplant diabetes. Hecking et al. have recently reported that a short treatment with insulin, administered immediately after transplantation, reduce the incidence of de novo diabetes one-year post-transplant. This study included 50 renal transplant patients and showed that a three months treatment of (Neutral Protamine Hagedorn) NPH insulin decreased HbA1c. The occurrence of diabetes, a secondary end-point, was reduced by 73% in the treated group.

No further pharmacological strategy has been developed to date. Relevant experimental evidences suggest that gliptins could be used in the pharmacological prevention of post-transplant diabetes. These drugs are inhibitors of dipeptidyl peptidase-4 (DPP-4), which inactivates the incretins, the glucagon-like peptide-1 (GLP-1) and the gastric inhibitory polypeptide (GIP). DPP-4 inhibition causes an increase in the GLP-1 and GIP concentrations which induce insulin secretion and inhibition of glucagon secretion. The gliptins are approved for the treatment of type 2 diabetes. Beyond the effects on blood glucose, gliptins have pleiotropic effects including a protective effect on β cells and anti-inflammatory effect.

The additional cost associated with new-onset diabetes after transplantation could be also significantly reduced by efficient prevention. A US study found that, for the period between 1994 and 1998, a newly diagnosed diabetic patient has cost $21,500 of medical expenses 2 years after transplantation. Moreover, transplantation resulting in one of the best increases of patients' quality of life, its estimate is essential in the treatment evaluation of this population.

03

Conditions studied

  • Disorder Related to Renal Transplantation
  • Diabetes

Browse trials for

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Major Patients (18 year old or older)
  • Signature of
  • Affiliation to a French social security or receiving such a scheme
  • Patient receiving a first kidney transplant
  • Patients considered at high risk of developing posttransplant diabetes having at least 2 of the 3 following criteria: Age> 50 years; greater than 30 kg/m²; Direct Family history of type 2 diabetes
  • Patients who can receive therapy including tacrolimus, mycophenolic acid and
  • Patients in whom the cessation of steroids may be considered at the latest at Month 3 post-transplant

Exclusion criteria

Exclusion Criteria:

  • Legal disability or limited legal capacity
  • Topic unlikely to cooperate in the study and / or low early cooperation by the investigator
  • Patient without health insurance
  • Pregnancy
  • Patient in the period of exclusion of another study or under the "national register of volunteers."
  • Inability to understand the reasons for the study; psychiatric disorders judged by the investigator to be incompatible with the inclusion in the study
  • Active infection
  • Infection with virus
  • A history of diabetes
  • Multi-Organ Transplantation
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
47 participants (actual)

Study arms

  • Active comparator
    Vildagliptin

    Group 1 will be treated with Vildagliptin 50 or 100 mg/day for 2 months, then 25 or 50 mg/d for 1 month depending on their creatinine assay.

    Drug: Vildagliptin

  • Placebo comparator
    Placebo

    Group 2 will be treated with placebo according to the same dosage.

    Drug: Placebo

Interventions

  • Galvus is prescribed as recommended by the marketing authorization. In adults, the recommended dose of Galvus is 100 mg per day (one tablet in the morning and another in the evening). In patients with moderate or severe kidney problems, the recommended dose is 50 mg once daily (one tablet in the morning). Patients with creatinine clearance greater than 50 ml/min the vildalgliptin dose will be 100 mg/day. For those whose clearance is less than 50 ml/min, the daily dose is 50 mg. The creatinine clearance will be measured each week. The treatment duration will be 3 months, divided into 2 months of complete treatment and one month of cessation treatment with half dose of vildagliptin.

    Also known as: Galvus

  • DrugPlacebo

    The placebo is the same as Galvus (packaging, shape, color, registration) but will contain only excipient. The given dose will also be identical.

    Also known as: Excipient

06

What researchers measure

Primary outcomes

  1. Diabetes event

    The primary endpoint is the proportion of diabetic patients 1 year after transplantation. Diabetic patients are defined as one of the following proposals: * Patients receiving a diabetic treatment * Patients have a fasting glucose above 7 mmol/l * Patients with an abnormal oral glucose tolerance test (OGTT)

    Time frame: 1 year

Secondary outcomes

  1. Glycemic control

    The criteria for secondary assessments are abnormal blood glucose measured by: the glycated hemoglobin (HbA1c) 3 months, 6 months and 12 months after transplantation.

    Time frame: 3, 6 and 12 months

  2. Acute rejection, infections, graft and patient survival

    The occurrence of acute rejection, infection, graft loss and patient death 3 months, 6 months and 12 months after transplantation.

    Time frame: 3, 6 and 12 months

  3. The health-related quality of life improvement

    The health-related quality of life (ReTRANSQOL questionnaire), 3 months, 6 months and 12 months after transplantation.

    Time frame: 3, 6 and 12 months

  4. The cost-effectiveness ratio

    The cost-effectiveness of prevention of diabetes with vildagliptin

    Time frame: 1 year

07

Study locations

1 site
  • CHU de Besançon
    Besançon, 25000, France
08

References and documents

Publications

  • Gaiffe E, Crepin T, Bamoulid J, Courivaud C, Buchler M, Cassuto E, Albano L, Chemouny JM, Choukroun G, Hazzan M, Kessler L, Legendre C, Le Meur Y, Ouali N, Thierry A, Anota A, Nerich V, Limat S, Bonnetain F, Vernerey D, Ducloux D. PRODIG (Prevention of new onset diabetes after transplantation by a short term treatment of Vildagliptin in the early renal post-transplant period) study: study protocol for a randomized controlled study. Trials. 2019 Jun 21;20(1):375. doi: 10.1186/s13063-019-3392-6. PubMed 31227028 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2018 to primary completion in Jun 2026, 91 months.

Of 63 non-industry phase 3 interventional studies under Diabetes Mellitus, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 79. This study's 91 months is above that.

Counting every sponsor, half of 230 studies reached it within 19 months; a quarter within 13 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2016
First posted
Jul 29, 2016
StartActual
Oct 26, 2018
Primary completionActual
Jun 5, 2026
CompletionActual
Jun 5, 2026
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT02849899
Collaborators
University Hospital, Tours, University Hospital, Lille, Recherche Clinique Paris Descartes Necker Cochin Sainte Anne, Amiens University Hospital, University Hospital, Brest, Rennes University Hospital, Tenon Hospital, Paris, Centre Hospitalier Universitaire de Nice, University Hospital, Strasbourg, France
Responsible party
Sponsor
First posted
Jul 29, 2016
Start date
Oct 26, 2018
Primary completion
Jun 5, 2026
Completion
Jun 5, 2026
Last update
Oct 6, 2026

Study contacts

Didier Ducloux, Pr.
principal investigator · Besançon University Hospital, Nephrology department

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vildagliptin

Start the discussion